newsfilter
← Latest News
Business Wire·

Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

New 6-month data supports COMP360’s potential to establish a new standard of care in TRD Data from positive COMP006 Phase 3 trial demonstrates durable benefit through at least 6 months further validating COMP360’s